Supplementary Data — Chlorpheniramine reduces COVID-19 risk: real-time meta analysis of 3 studies

@CovidAnalysis, December 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACCROS-I Valerio-.. (DB RCT) 61% 0.39 [0.24-0.63] no recov. 61 (n) 40 (n) Improvement, RR [CI] Treatment Control ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.09-1.24] no recov. 3/61 6/40 ACCROS-I Valerio-.. (DB RCT) 89% 0.11 [0.01-0.87] no recov. 1/61 6/40 ACCROS-I Valerio-.. (DB RCT) 53% 0.47 [0.22-1.02] no recov. 10/61 14/40 ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.06-1.71] no recov. 2/61 4/40 ACCROS-I Valerio-.. (DB RCT) 59% 0.41 [0.14-1.16] no recov. 5/61 8/40 ACCROS-I Valerio-.. (DB RCT) 74% 0.26 [0.12-0.58] PASC 55 (n) 46 (n) ACCROS-II Valerio-Pascua 54% 0.46 [0.36-0.58] recov. time 330 (n) 330 (n) Sanchez-.. (DB RCT) 87% 0.13 [0.01-2.46] hosp. 0/32 2/13 Chlorpheniramine COVID-19 outcomes c19early.org December 2025 Favors chlorpheniramine Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.